Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Convertible Debt (2016 - 2021)

Fortress Biotech (FBIO) has 3 years of Convertible Debt data on record, last reported at $18.1 million in Q3 2021.

  • For Q3 2021, Convertible Debt changed N/A year-over-year to $18.1 million; the TTM value through Sep 2021 reached $18.1 million, changed N/A, while the annual FY2017 figure was $10.1 million, 175.14% up from the prior year.
  • Convertible Debt reached $18.1 million in Q3 2021 per FBIO's latest filing, up from $12.5 million in the prior quarter.
  • Across five years, Convertible Debt topped out at $18.1 million in Q3 2021 and bottomed at $1.5 million in Q2 2017.